Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“IASLC 2026 WCLC Presidential Symposium 1 Abstracts are out and here is why they matter:
- PL02.01: MAVERICK: Could fundamentally change the role of PCI in SCLC, particularly in the MRI-surveillance era.
- PL02.03: TAISHAN-302 Tam-Peli, a B7-H3 ADC, vs topotecan in relapsed SCLC
- Major test of B7-H3 ADCs in SCLC; potentially another option
- PL02.04: ARTEMIS-008 – Risvutatug rezetecan vs topotecan in relapsed SCLC
- 1st reported positive phase III OS study of a B7-H3 ADC in SCLC.
- PL02.06: EVOKE-03 Sacituzumab govitecan + pembro in PD-L1 TPS ≥50% metastatic NSCLC
- Tests whether adding a TROP-2 ADC to immunotherapy can improve first-line treatment beyond pembrolizumab alone- would magnitude of benefit overcome extra toxicity?
When there is so much to cover that you have to add a 2nd Presidential Symposium. Here is my take on why these abstracts matter:
- PL03.01: ADAURA 8-year OS landmark update of adjuvant osimertinib
- Looking at durability of benefit years after completing osimertinib and who could potentially benefit from continuation of therapy.
- PL03.03: PAPILLON – More data on benefit of amivantamab + chemo in EGFR exon 20 ins
- PL03.04: REZILIENT 3 zipalertinib + chemo in EGFR exon 20ins NSCLC
- A competing first-line strategy for EGFR exon 20ins
- PL03.06: ARROS-1 – zidesamtinib in TKI-naïve ROS1+ NSCLC
- Another potential ROS1 therapy (already approved ) with higher CNS-activity and good toxicity profile
- PL03.08: DESTINY-Lung04 – Moving trastuzumab deruxtecan #TDxd as 1st line therapy for HER2+ lung cancer (competes with Zongertinib already approved).”
Other articles about WCLC26 on OncoDaily.